N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study

References

• Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M, Maes M. The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol. Epub ahead of print 18 April. 2014 DOI: 10.1007/s12035-014-8705-x.
   Web of Science ®Google Scholar
• Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34:167–77.
   PubMed Web of Science ®Google Scholar
• Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Exp Opin Biol Ther 2008;8:1955–62.
   PubMed Web of Science ®Google Scholar
• Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm J. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatr 2007;31:389–94.
   PubMed Web of Science ®Google Scholar
• Zhou W, Kalivas PW. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatr 2008;63:338–40.
   PubMed Web of Science ®Google Scholar
• Azevedo E, Mendes AC, Berk M, Brietzke E. Systematic review of N-acetylcysteine in the treatment of addictions. Rev Bras Psiquiatr Epub ahead of print 18 may 2014 DOI: 10.1590/1516-4446-2013-1244.
   Web of Science ®Google Scholar
• Bossert JM, Liu SY, Lu L, Shaham A. A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking. J Neurosci 2004;24:10726–30.
   PubMed Web of Science ®Google Scholar
• Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, Van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double blind placebo-controlled pilot study. Eur Addict Res 2011;17:211–16.
   PubMed Web of Science ®Google Scholar
• Dean O, Giorland F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatr Neurosci 2011;36:78–86.
   PubMed Web of Science ®Google Scholar
• Kalivas P, Volkow N. The neural of addiction: a pathology of motivation and choice. Am J Psychiatr 2005;162:1403–13.
   PubMed Web of Science ®Google Scholar
• Koob G. Neurobiology of addiction. Focus. 2011;9:55–65.
   Google Scholar
• Gould NS, Min E, Gauthier S, Martin RJ, Day BJ. Lung glutathione adaptive responses to cigarette smoke exposure. Respiratory Res 2011;12:133.
   PubMed Web of Science ®Google Scholar
• Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M, Grier MD, Baker DA. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007;27:13968–76.
   PubMed Web of Science ®Google Scholar
• Knackstedt LA, LaRowe S, Mardikian P, Malcom R, Upadhyaya H, Hedden S, Markou A, Kalivas PW. The role of cystine glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatr 2009;65:841–5.
   PubMed Web of Science ®Google Scholar
• Bortolasci CC, Vargas HO, Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, Berk M, Dodd S, Maes M. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord 2014;159:23–30.
   PubMed Web of Science ®Google Scholar
• Nunes SOV, De Castro MRP, Watanabe MAW, Guembarovski RL, Vargas HO, Reiche EM, Kaminami HM, Dodd S, Berk M. Genetic polymorphisms in glutathione-S-transferases are associated with anxiety and mood disorders in nicotine dependence. Psychiatr Genet 2014;24:87–93.
   PubMed Web of Science ®Google Scholar
• Antonelli RC. Nicotine-related disorders. In: Gabbard, GO Gabbard's treatment of Psychiatric disorders- DSM-5 Edition. (5th edn) Washington: American Psychiatric Publishing. 2014; pp. 871–83.
   Google Scholar
• Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatr 2008;64:361–58.
   PubMed Web of Science ®Google Scholar
• Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatr 2014;75:628–36.
   PubMed Web of Science ®Google Scholar
• Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008;29:346–51.
   PubMed Web of Science ®Google Scholar
• Del Ben CM, Vilela JAA, Crippa JAS, Hallak JEC, Labate CM, Zuardi AW. Reliability of the ‘Structured Clinical Interview for DSM – IV’ - clinical version translated into Portuguese. Rev Bras Psychiatr 2001;23:156–9.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Quitting smoking among adults: United States, 2001–2011. MMWR Morb Mortal Weekly Rep 2011;60:1513–9.
   PubMedGoogle Scholar
• Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med 1989;12:159–82.
   PubMed Web of Science ®Google Scholar
• Carmo JT, Pueyo AA. Adaptation to Portuguese of the Fagerstrom Test for Nicotine Dependence (FTND) to assess dependence and tolerance to nicotine in smokers. Rev Bras Med 2002;59:73–80.
   Google Scholar
• Storr CL, Reboussin BA, Anthony JC. The Fagerstrom test for nicotine dependence : a comparison of standard scoring and latent class analysis approaches. Drug Alcohol Depend 2005;80:241–250.
   PubMed Web of Science ®Google Scholar
• Reichert J, Araújo AJ, Gonçalves CMC, Godoy I, Chatkin JM, Sales MPU, Santos SRRA. BTA guidelines: guidelines for smoking cessation - 2008. J Bras Pneumol 2008;34:845–80.
   PubMedGoogle Scholar
• Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest 2000;117:758–63.
   PubMed Web of Science ®Google Scholar
• Moreno RA, Moreno DH. Hamilton and Montgomery & Asberg depression rating scales. Rev Psychiatr Clin 1998;25:262–72.
   Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurements of disability. Int Clin Psychopharmacol 1996;3(III Suppl.):89–95.
   Google Scholar
• Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematous. Arthr Rheumat 2013;65:1313–18.
   PubMed Web of Science ®Google Scholar
• Pasco JA, Williams LJ, Jacka FN, Ng F, Henry MJ, Nicholson GC, Kotowicz MA. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Brit J Psychiatr 2008;193:322–6.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Georg T, Mc Knee S. Differences in smoking expectancies in smokers with and without a history of major depression. Addict Beh 2011;36:434–7.
   PubMed Web of Science ®Google Scholar
• Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ 2014;13:348, g1151.
   Google Scholar
• American Psychiatric Association. Tobacco-related disorders of DSM-5. In: American Psychiatric Association, Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: APA; 2013. p. 571–7.
   Google Scholar
• Nunes SOV, De Castro MRP, Vargas HO, Vargas MM, Machado RCBR, Fonseca ICB, Dodd S, Berk M. Clinical characteristics and smoking cessation: an analysis of sex and depressive disorders differences. Addict Disord Treatm 2013;12:158–65.
   Google Scholar
• Souza GA, Ebaid GX, Seiva FR, Rocha KH, Galhardi CM, Mani F, Novelli EL. N-acetylcysteine an allium plant compound improves high-sucrose diet-induced obesity and related effects. Evid Based Compl Altern Med 2011;8:1–7.
   Google Scholar
• Nunes SO, Vargas HO, Brum J, Prado E, Vargas MM, Castro MR, Berk M. A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tob Res 2012;14:540–6.
   PubMed Web of Science ®Google Scholar
• Pizzo de Castro MR, Maes M, Guembarovski RL, Ariza CB, Reiche EM, Vargas HO, Vargas MM, de Melo LG, Dodd S, Berk M, Watanabe MA, Nunes SO. SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. BMC Genet 2014;15:78.
   PubMedGoogle Scholar
• Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764–85.
   PubMed Web of Science ®Google Scholar
• O'Loughlin J, Lambert M, Karp I, McGrath J, Gray-Donald K, Barnett TA, Delvin EE, Levy E, Paradis G. Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. Nicotine Tob Res 2008;10:525–32.
   PubMed Web of Science ®Google Scholar
• Hernandez-Lopes S, Gardunõ J, Mihailescu S. Nicotinic modulation of serotonergic activity in the dorsal raphe nucleus. Rev Neurosci 2013;24:455–69.
   PubMed Web of Science ®Google Scholar
• Khadrawy YA, El-Shamy KAI, Mohamed SI. Nicotine restores monoamine neurotransmitter changes in the cortex and hippocampus of reserpinized rats as a model of depression. Eur Rev Med Pharmacol Sci 2011;15:863–70.
   PubMed Web of Science ®Google Scholar
• Vieyra-Reyes P, Venebra-Muñoz A, Rivas-Santiago B, García-García F. Acción de la nicotina como antidepresivo y regulador del sueño en sujetos deprimidos. Rev Neurol 2009;49:661–7.
   PubMedGoogle Scholar
• Chitty KM, Lagopoulos J, Hickie IB, Hermens DF. The impact of alcohol and tobacco use on in vivo glutathione in youth with bipolar disorder: an exploratory study. J Psychiatr Res 2014; 55:59–67.
   PubMedGoogle Scholar